Advertisement
11/23/2020

AstraZeneca’s Oxford COVID-19 vaccine found to be highly effective

Sandra Levy
Senior Editor
Sandra Levy profile picture

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed AstraZeneca's AZD1222 vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalizations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis.

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine showed 90% efficacy in one dosing regimen, when the vaccine was given as a half dose, followed by a full dose at least one month apart, and 62% efficacy in a second regimen, when two full doses were given at least one month apart. That averages to a 70% efficacy, said AstraZeneca.

The news comeds after Moderna announced earlier this month that its vaccine was 94.5% effective against COVID-19, and Pfizer announced its vaccine was 95% effective.

Professor Andrew Pollard, chief investigator of the Oxford Vaccine trial at Oxford, said: “These  findings  show  that  we  have  an  effective  vaccine  that  will  save  many  lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks  to  the  many  volunteers  in  our  trial,  and  the  hard  working  and  talented  team  of  researchers based around the world.”

Pascal Soriot, AstraZeneca CEO, said: “Today marks an important milestone in our fight against the pandemic. This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency. Furthermore, the vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval.”

AstraZeneca noted that it is making rapid progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. The vaccine can be stored, transported and handled at normal refrigerated conditions (2-8 degrees Celsius/ 36-46 degrees Fahrenheit) for at least six months and administered within existing healthcare settings.

 

Advertisement
Advertisement